tiprankstipranks
Trending News
More News >
PolyPeptide Group AG (CH:PPGN)
:PPGN
Advertisement

PolyPeptide Group AG (PPGN) AI Stock Analysis

Compare
0 Followers

Top Page

CH:PPGN

PolyPeptide Group AG

(PPGN)

Rating:60Neutral
Price Target:
CHF25.00
▼(-12.13% Downside)
PolyPeptide Group AG's stock score is primarily influenced by its mixed financial performance and strong technical momentum. While the company shows revenue growth and improved cash flow management, ongoing profitability challenges and a negative P/E ratio weigh on its valuation. The technical indicators suggest positive momentum, but potential overbought conditions warrant caution. The absence of earnings call data and corporate events means these factors do not influence the score.

PolyPeptide Group AG (PPGN) vs. iShares MSCI Switzerland ETF (EWL)

PolyPeptide Group AG Business Overview & Revenue Model

Company DescriptionPolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
How the Company Makes MoneyPolyPeptide Group AG generates revenue primarily through contract development and manufacturing services for peptide-based APIs. The company's key revenue streams include custom peptide synthesis, process development, and large-scale commercial manufacturing. By leveraging its advanced technological capabilities and expertise in peptide chemistry, PolyPeptide Group offers tailored solutions to its clients, enabling them to bring their peptide therapeutics from conception to market. The company benefits from long-term relationships with its clients, repeat business, and strategic partnerships in the pharmaceutical industry. Additionally, PolyPeptide Group's revenue is supported by its continuous investment in state-of-the-art facilities and adherence to stringent regulatory standards, ensuring high-quality production that meets the demands of global markets.

PolyPeptide Group AG Financial Statement Overview

Summary
PolyPeptide Group AG exhibits a mixed financial performance with revenue growth and improvements in cash flow management being positive aspects. However, ongoing net losses and negative EBIT continue to pose significant profitability challenges. The balance sheet shows stability with low leverage, but poor return on equity highlights the impact of these losses.
Income Statement
45
Neutral
PolyPeptide Group AG's revenue has shown growth, increasing from 2023 to 2024 by 5.72%. However, the company faces challenges with profitability, marked by a negative net profit margin of -5.77% in 2024. The EBIT and EBITDA margins have improved compared to the prior year, but EBIT remains negative at -2.17%, indicating ongoing operational challenges. Despite revenue growth, overall profitability remains a concern.
Balance Sheet
65
Positive
The company maintains a healthy equity ratio of 47.22% in 2024, highlighting a strong equity base relative to total assets. The debt-to-equity ratio stands at 0.26, indicating manageable leverage levels. However, return on equity is negative at -5.48%, reflecting the impact of net losses on shareholder returns. The balance sheet shows stability with low leverage risk, but profitability challenges persist.
Cash Flow
70
Positive
PolyPeptide Group AG demonstrated significant improvement in cash flow, with operating cash flow to net income ratio at -4.57, suggesting efficient cash operations despite net losses. Free cash flow turned positive in 2024, showing a growth trajectory from a negative base, indicating effective management of capital expenditures. The company exhibits strong cash flow management, which is a positive sign for future financial stability.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue338.69M320.37M280.98M282.13M224.30M
Gross Profit39.27M4.77M51.99M99.70M73.19M
EBITDA28.42M-22.15M35.72M83.35M58.55M
Net Income-19.56M-51.44M7.77M47.26M31.34M
Balance Sheet
Total Assets756.58M689.09M575.78M595.04M375.98M
Cash, Cash Equivalents and Short-Term Investments68.28M95.71M37.53M136.30M17.21M
Total Debt94.12M113.66M21.22M18.00M37.43M
Total Liabilities399.33M307.86M154.10M173.87M198.31M
Stockholders Equity357.24M381.23M421.68M421.17M177.66M
Cash Flow
Free Cash Flow2.43M-20.25M-69.64M-16.61M8.86M
Operating Cash Flow89.40M36.48M5.46M57.35M49.48M
Investing Cash Flow-91.02M-59.51M-78.44M-80.84M-42.56M
Financing Cash Flow-25.32M84.55M-26.87M130.93M-6.73M

PolyPeptide Group AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price28.45
Price Trends
50DMA
21.96
Positive
100DMA
20.00
Positive
200DMA
22.83
Positive
Market Momentum
MACD
1.38
Negative
RSI
71.88
Negative
STOCH
86.52
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:PPGN, the sentiment is Positive. The current price of 28.45 is above the 20-day moving average (MA) of 23.65, above the 50-day MA of 21.96, and above the 200-day MA of 22.83, indicating a bullish trend. The MACD of 1.38 indicates Negative momentum. The RSI at 71.88 is Negative, neither overbought nor oversold. The STOCH value of 86.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:PPGN.

PolyPeptide Group AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
CHF37.88B52.32
0.72%5.93%29.83%
60
Neutral
CHF898.45M
12.03%-19.31%
51
Neutral
$7.73B-0.08-44.86%2.23%22.72%-1.44%
CHF5.17B38.7110.07%1.25%
$4.88B27.1118.36%0.43%
$26.27B114.132.64%
71
Outperform
CHF31.36B95.53
0.11%6.22%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CH:PPGN
PolyPeptide Group AG
28.75
-4.00
-12.21%
CH:LONN
Lonza Group Ltd
560.20
3.89
0.70%
GB:0QND
Bachem Holding AG
67.65
-14.03
-17.18%
SGFEF
Siegfried Holding AG
114.35
11.58
11.27%
SDZXF
Sandoz Group Ltd
59.80
16.70
38.75%
CH:GALD
Galderma Group AG
135.20
55.12
68.83%

PolyPeptide Group AG Corporate Events

PolyPeptide Group Reports Strong First Half 2025 Growth and Raises Forecast
Aug 12, 2025

PolyPeptide Group AG reported a 24% revenue growth in the first half of 2025, driven by the successful start-up of its new SPPS large-scale plant in Belgium and positive market trends. The company adjusted its annual forecast upwards, reflecting confidence in its growth strategy and operational excellence. Despite increased material costs and extraordinary expenses, EBITDA improved significantly. The company also expanded its credit facility to enhance financial flexibility, while continuing to invest in capacity expansion at its global sites.

The most recent analyst rating on (CH:PPGN) stock is a Buy with a CHF45.00 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

PolyPeptide Expands Credit Facility to Fuel Growth
May 23, 2025

PolyPeptide Group AG has expanded its revolving credit facility by EUR 40 million to EUR 151 million, with an extension until March 2028, supported by UBS, Danske Bank, and Zürcher Kantonalbank. This financial boost, alongside increased support from main shareholder Draupnir Holding B.V., enhances PolyPeptide’s financial flexibility to pursue growth, aiming to double its 2023 revenues by 2028, particularly in the metabolic diseases and GLP-1 sectors.

The most recent analyst rating on (CH:PPGN) stock is a Hold with a CHF33.50 price target. To see the full list of analyst forecasts on PolyPeptide Group AG stock, see the CH:PPGN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025